Abstract
Health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19) are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, to our knowledge, there is no effective pharmacologic prophylaxis for individuals at risk. To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy. This randomized, double-blind, placebo-controlled clinical trial (the Prevention and Treatment of COVID-19 With Hydroxychloroquine Study) was conducted at 2 tertiary urban hospitals, with enrollment from April 9, 2020, to July 14, 2020; follow-up ended August 4, 2020. The trial randomized 132 full-time, hospital-based HCWs (physicians, nurses, certified nursing assistants, emergency technicians, and respiratory therapists), of whom 125 were initially asymptomatic and had negative results for SARS-CoV-2 by nasopharyngeal swab. The trial was terminated early for futility before reaching a planned enrollment of 200 participants. Hydroxychloroquine, 600 mg, daily, or size-matched placebo taken orally for 8 weeks. The primary outcome was the incidence of SARS-CoV-2 infection as determined by a nasopharyngeal swab during the 8 weeks of treatment. Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants. Of the 132 randomized participants (median age, 33 years [range, 20-66 years]; 91 women [69%]), 125 (94.7%) were evaluable for the primary outcome. There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo (4 of 64 [6.3%] vs 4 of 61 [6.6%]; P > .99). Mild adverse events were more common in participants taking hydroxychloroquine compared with placebo (45% vs 26%; P = .04); rates of treatment discontinuation were similar in both arms (19% vs 16%; P = .81). The median change in QTc (baseline to 4-week evaluation) did not differ between arms (hydroxychloroquine: 4 milliseconds; 95% CI, -9 to 17; vs placebo: 3 milliseconds; 95% CI, -5 to 11; P = .98). Of the 8 participants with positive results for SARS-CoV-2 (6.4%), 6 developed viral symptoms; none required hospitalization, and all clinically recovered. In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. ClinicalTrials.gov Identifier: NCT04329923.
Highlights
Author Affiliations: Author affiliations are listed at the end of this article
We sought to test the hypothesis that administering daily hydroxychloroquine would prevent SARS-CoV-2 infection in hospital-based Health care workers (HCWs) over 8 weeks of exposure via reverse-transcriptase polymerase chain reaction (RT-PCR) testing of nasopharyngeal (NP) swabs and serologic antibody testing from participants at baseline, 4 weeks, and 8 weeks of treatment. This single-health system, double-blind placebo-controlled randomized trial was conducted as the prophylaxis substudy of the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) investigations at 2 hospitals within the Penn Medicine system: the Hospital of the University of Pennsylvania, a 839-bed teaching hospital, and Penn Presbyterian Medical Center, a 375-bed teaching hospital (Philadelphia, Pennsylvania)
Statistical Power and Analysis With the assumption of a 10% infection rate in the HCW population, we considered rejecting the null hypothesis if the infection rate was 1% with hydroxychloroquine treatment
Summary
This single-health system, double-blind placebo-controlled randomized trial was conducted as the prophylaxis substudy of the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) investigations at 2 hospitals within the Penn Medicine system: the Hospital of the University of Pennsylvania, a 839-bed teaching hospital, and Penn Presbyterian Medical Center, a 375-bed teaching hospital (Philadelphia, Pennsylvania).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.